Mineral

Magnesium Citrate

Magnesium citrate

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

200 to 400 mg/day elemental magnesium, adjusted for stool tolerance

watchEffect Window

Stool effects can occur quickly. Repletion effects take longer.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Magnesium citrate is a practical, reasonably bioavailable magnesium form that is useful for repletion and can also loosen stools, but it is not uniquely better than other well-absorbed forms for most non-GI goals.

Magnesium citrate sits in the middle of the magnesium-form landscape. It is more bioavailable than magnesium oxide and often cheaper than glycinate, but it is also more likely to loosen stools. That makes it a reasonable choice when someone wants both magnesium repletion and mild bowel support. It is less ideal when the main goal is maximum GI tolerance or when diarrhea would be counterproductive.

Magnesium citrate works by delivering magnesium, not by acting as a unique magnesium-specific signaling compound. The citrate carrier improves practical bioavailability compared with oxide and also contributes to the form’s stool-loosening tendency.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Reasonably effective magnesium repletion
  • Mild bowel-loosening effect in some users

Secondary Outcomes

  • Better bioavailability than magnesium oxide
  • No clear evidence of unique superiority over other well-absorbed forms for most non-GI outcomes

Safety

Contraindications and Interactions

Contraindications

  • Severe kidney impairment
  • Active diarrhea

Side effects

  • Loose stools or diarrhea
  • Abdominal cramping

Interactions

  • Levothyroxine, tetracyclines, fluoroquinolones, and bisphosphonates

Avoid if

  • You need a magnesium form with minimal GI effect
  • You have significant kidney disease without clinician guidance

Evidence

Study-level References

mc-SRC-001Randomized crossover trial
Sourceopen_in_new

Lindberg JS, Zobitz MM, Poindexter JR, Pak CY. Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr. 1990;9(1):48-55. PMID:2407766.

Population: Healthy volunteers.

Dose protocol: Trial-specific magnesium citrate versus magnesium oxide comparison

Key findings: Magnesium citrate showed higher bioavailability than magnesium oxide.

Notes: Classic foundational form-comparison study.

Paper content

This classic bioavailability study is still useful for magnesium citrate because it directly compared citrate with oxide and found better absorption with the citrate form. It does not prove unique clinical superiority for every endpoint, but it supports the practical view that magnesium citrate is a reasonable repletion form and usually more evidence aligned than oxide when people want absorbed magnesium rather than just a laxative effect.

mc-SRC-002Randomized crossover trial
Sourceopen_in_new

Schuette SA, Lashner BA, Janghorbani M. Assessment of bioavailability of Mg from Mg citrate and Mg oxide by measuring urinary excretion and serum levels after single-dose administration in a randomized crossover study. Nutrients. 2020;12(3):867. doi:10.3390/nu12030867. PMID:32162607.

Population: Magnesium-saturated healthy adults.

Dose protocol: 300 mg elemental magnesium single dose

Key findings: Magnesium citrate produced stronger urinary and serum magnesium responses than magnesium oxide.

Notes: Good modern confirmation study.

Paper content

This modern crossover trial confirms the older finding that magnesium citrate is more bioavailable than oxide, even after a single dose. It is most useful for form selection, not for proving that magnesium citrate has unique disease-specific benefits versus other absorbable forms such as glycinate.

mc-SRC-003Randomized, double-blind, placebo-controlled pilot trial.
Sourceopen_in_new

Afitska K, Clavel T, Kisters K, Vormann J, Werner T. Magnesium citrate supplementation decreased blood pressure and HbA1c in normomagnesemic subjects with metabolic syndrome. Magnes Res. 2021;34(3):130-139. doi:10.1684/mrh.2021.0489. PMID:34859788.

Population: Adults with metabolic syndrome and normal magnesium levels.

Dose protocol: 400 mg magnesium citrate daily for 12 weeks versus placebo

Key findings: Blood pressure decreased from 145/85 to 121/79 mmHg. HbA1c decreased from 6.43% to 6.15%. Benefit seen even in normomagnesemic subjects.

Notes: Very small pilot (n=24) but notable for showing benefit in subjects with normal baseline serum magnesium.

Paper content

This small pilot RCT tested 400 mg magnesium citrate daily for 12 weeks in 24 adults with metabolic syndrome who had normal baseline magnesium levels. Blood pressure fell substantially from 145/85 to 121/79 mmHg in the treatment group, and HbA1c decreased from 6.43% to 6.15%. Plasma magnesium increased only in the treatment group. The study is notable because it showed benefit even in normomagnesemic subjects, suggesting that standard serum magnesium may underestimate functional deficiency in metabolic syndrome. However, the sample size is very small (n=24) and results should be considered preliminary.

Guides

Setup

Help